Bausch Health Companies Inc.

BMV:BHC N Stock Report

Market Cap: Mex$61.6b

Bausch Health Companies Valuation

Is BHC N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BHC N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BHC N (MX$200.19) is trading below our estimate of fair value (MX$1021.4)

Significantly Below Fair Value: BHC N is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BHC N?

Key metric: As BHC N is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BHC N. This is calculated by dividing BHC N's market cap by their current revenue.
What is BHC N's PS Ratio?
PS Ratio0.3x
SalesUS$9.47b
Market CapUS$2.99b

Price to Sales Ratio vs Peers

How does BHC N's PS Ratio compare to its peers?

The above table shows the PS ratio for BHC N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.3x
LAB B Genomma Lab Internacional. de
1.4x9.9%Mex$24.6b
600535 Tasly Pharmaceutical Group
2.5x6.9%CN¥21.7b
600062 China Resources Double-Crane PharmaceuticalLtd
2.1x8.9%CN¥21.4b
600329 Tianjin Pharmaceutical Da Ren Tang Group
3.1x10.9%CN¥21.3b
BHC N Bausch Health Companies
0.3x1.5%Mex$3.0b

Price-To-Sales vs Peers: BHC N is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (2.3x).

Price to Sales Ratio vs Industry

How does BHC N's PS Ratio compare vs other companies in the Global Pharmaceuticals Industry?

192 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.6x9.2%
BHC N Bausch Health Companies
 0.3x1.5%US$2.99b
BHC N 0.3xIndustry Avg. 2.6xNo. of Companies191PS02.44.87.29.612+
192 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.6x19.6%
BHC N Bausch Health Companies
 0.3x218.3%US$2.99b
No more companies

Price-To-Sales vs Industry: BHC N is good value based on its Price-To-Sales Ratio (0.3x) compared to the Global Pharmaceuticals industry average (2.6x).

Price to Sales Ratio vs Fair Ratio

What is BHC N's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BHC N PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BHC N's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BHC N forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
Mex$173.80
0%
36.8%Mex$243.32Mex$60.83n/a7
Nov ’25Mex$200.19
Mex$165.85
-17.2%
35.2%Mex$240.19Mex$60.05n/a7
Oct ’25n/a
Mex$154.33
0%
32.0%Mex$231.50Mex$57.87n/a8
Sep ’25Mex$118.20
Mex$153.72
+30.0%
31.5%Mex$234.24Mex$58.56n/a8
Aug ’25Mex$108.91
Mex$160.74
+47.6%
35.7%Mex$244.04Mex$56.32n/a8
Jul ’25Mex$115.00
Mex$165.18
+43.6%
20.0%Mex$219.43Mex$118.16n/a7
Jun ’25n/a
Mex$165.18
0%
20.0%Mex$219.43Mex$118.16n/a7
May ’25n/a
Mex$177.59
0%
26.9%Mex$274.35Mex$120.03n/a7
Apr ’25Mex$174.30
Mex$166.83
-4.3%
30.6%Mex$272.77Mex$119.34n/a7
Mar ’25n/a
Mex$166.83
0%
30.6%Mex$272.77Mex$119.34n/a7
Feb ’25n/a
Mex$163.31
0%
33.6%Mex$275.05Mex$103.14n/a7
Jan ’25n/a
Mex$163.31
0%
33.6%Mex$275.05Mex$103.14n/a7
Dec ’24n/a
Mex$163.31
0%
33.6%Mex$275.05Mex$103.14n/a7
Nov ’24n/a
Mex$172.56
0%
33.6%Mex$290.63Mex$108.98Mex$200.197
Oct ’24n/a
Mex$168.08
0%
32.6%Mex$278.90Mex$104.59n/a7
Sep ’24n/a
Mex$142.42
0%
20.6%Mex$201.06Mex$100.53Mex$118.207
Aug ’24Mex$155.00
Mex$144.25
-6.9%
20.8%Mex$201.94Mex$100.97Mex$108.917
Jul ’24n/a
Mex$146.29
0%
22.5%Mex$206.52Mex$103.26Mex$115.006
Jun ’24Mex$140.18
Mex$220.71
+57.5%
82.7%Mex$626.35Mex$107.37n/a6
May ’24Mex$128.00
Mex$237.40
+85.5%
75.2%Mex$635.09Mex$127.02n/a6
Apr ’24n/a
Mex$263.52
0%
75.3%Mex$658.81Mex$131.76Mex$174.305
Mar ’24n/a
Mex$245.01
0%
73.1%Mex$643.16Mex$128.63n/a6
Feb ’24Mex$158.00
Mex$232.82
+47.4%
81.0%Mex$679.05Mex$116.41n/a7
Jan ’24n/a
Mex$237.12
0%
81.0%Mex$691.61Mex$118.56n/a7
Dec ’23n/a
Mex$234.21
0%
81.0%Mex$683.10Mex$117.10n/a7
Nov ’23n/a
Mex$253.29
0%
90.7%Mex$796.87Mex$99.61n/a7

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

CSPC Pharmaceutical Group

HK$69.4b

An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.

1093 N

HK$15.69

7D

0%

1Y

-27.0%

Exact Sciences

US$13.1b

Provides cancer screening and diagnostic test products in the United States and internationally.

EXAS *

US$872.00

7D

0%

1Y

n/a

Novartis

CHF 183.8b

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.

NOVN N

CHF 2,236.00

7D

0%

1Y

n/a